EXAS vs. FMS: A Head-to-Head Stock Comparison
Updated onHere’s a clear look at EXAS and FMS, comparing key factors like historical performance, profitability, financial strength, growth, dividend, and valuation.
Company Profile
EXAS is a standard domestic listing, while FMS trades as an American Depositary Receipt (ADR), offering U.S. investors access to its foreign-listed shares.
| Symbol | EXAS | FMS |
|---|---|---|
| Company Name | Exact Sciences Corporation | Fresenius Medical Care AG |
| Country | United States | Germany |
| GICS Sector | Health Care | Health Care |
| GICS Industry | Biotechnology | Health Care Providers & Services |
| Market Capitalization | 12.87 billion USD | 13.50 billion USD |
| Exchange | NasdaqCM | NYSE |
| Listing Date | February 1, 2001 | September 17, 1996 |
| Security Type | Common Stock | ADR |
Historical Performance
This chart compares the performance of EXAS and FMS by tracking the growth of an initial $10,000 investment in each. Use the tabs to select the desired time period. Data is adjusted for dividends and splits.
Historical Performance at a Glance
| Symbol | EXAS | FMS |
|---|---|---|
| 5-Day Price Return | 0.68% | -1.68% |
| 13-Week Price Return | 47.00% | -5.40% |
| 26-Week Price Return | 24.89% | -21.70% |
| 52-Week Price Return | 32.13% | -2.93% |
| Month-to-Date Return | 3.62% | -13.12% |
| Year-to-Date Return | 19.29% | -8.40% |
| 10-Day Avg. Volume | 3.67M | 0.91M |
| 3-Month Avg. Volume | 2.86M | 0.58M |
| 3-Month Volatility | 29.23% | 27.67% |
| Beta | 1.43 | 0.70 |
Profitability
Return on Equity (TTM)
EXAS
-40.39%
Biotechnology Industry
- Max
- 96.19%
- Q3
- 12.45%
- Median
- -16.39%
- Q1
- -47.43%
- Min
- -131.19%
EXAS has a negative Return on Equity of -40.39%. This indicates the company is generating a loss for its shareholders, which can be a result of unprofitability or negative shareholder equity and is often a sign of financial distress.
FMS
4.70%
Health Care Providers & Services Industry
- Max
- 24.67%
- Q3
- 15.54%
- Median
- 8.37%
- Q1
- 5.49%
- Min
- -2.09%
FMS’s Return on Equity of 4.70% is in the lower quartile for the Health Care Providers & Services industry. This indicates a less efficient generation of profit from its equity base when compared to its competitors.
Net Profit Margin (TTM)
EXAS
-32.01%
Biotechnology Industry
- Max
- 84.13%
- Q3
- 19.34%
- Median
- -1.39%
- Q1
- -117.64%
- Min
- -296.77%
EXAS has a negative Net Profit Margin of -32.01%, indicating the company is operating at a net loss as its expenses exceeded its revenues.
FMS
3.36%
Health Care Providers & Services Industry
- Max
- 9.33%
- Q3
- 4.80%
- Median
- 2.90%
- Q1
- 0.93%
- Min
- -3.28%
FMS’s Net Profit Margin of 3.36% is aligned with the median group of its peers in the Health Care Providers & Services industry. This indicates its ability to convert revenue into profit is typical for the sector.
Operating Profit Margin (TTM)
EXAS
-32.45%
Biotechnology Industry
- Max
- 78.85%
- Q3
- 20.86%
- Median
- 0.51%
- Q1
- -128.29%
- Min
- -315.84%
EXAS has a negative Operating Profit Margin of -32.45%. This signifies the company is unprofitable at the operational level, as its core business expenses exceed its revenue.
FMS
7.57%
Health Care Providers & Services Industry
- Max
- 18.35%
- Q3
- 8.71%
- Median
- 5.10%
- Q1
- 2.10%
- Min
- -3.07%
FMS’s Operating Profit Margin of 7.57% is around the midpoint for the Health Care Providers & Services industry, indicating that its efficiency in managing core business operations is typical for the sector.
Profitability at a Glance
| Symbol | EXAS | FMS |
|---|---|---|
| Return on Equity (TTM) | -40.39% | 4.70% |
| Return on Assets (TTM) | -16.91% | 2.02% |
| Net Profit Margin (TTM) | -32.01% | 3.36% |
| Operating Profit Margin (TTM) | -32.45% | 7.57% |
| Gross Profit Margin (TTM) | 67.37% | 24.67% |
Financial Strength
Current Ratio (MRQ)
EXAS
2.72
Biotechnology Industry
- Max
- 15.83
- Q3
- 7.97
- Median
- 4.06
- Q1
- 2.64
- Min
- 0.72
EXAS’s Current Ratio of 2.72 aligns with the median group of the Biotechnology industry, indicating that its short-term liquidity is in line with its sector peers.
FMS
1.44
Health Care Providers & Services Industry
- Max
- 2.00
- Q3
- 1.56
- Median
- 1.28
- Q1
- 0.92
- Min
- 0.01
FMS’s Current Ratio of 1.44 aligns with the median group of the Health Care Providers & Services industry, indicating that its short-term liquidity is in line with its sector peers.
Debt-to-Equity Ratio (MRQ)
EXAS
0.94
Biotechnology Industry
- Max
- 1.27
- Q3
- 0.62
- Median
- 0.13
- Q1
- 0.00
- Min
- 0.00
EXAS’s leverage is in the upper quartile of the Biotechnology industry, with a Debt-to-Equity Ratio of 0.94. While this approach can boost equity growth, it also exposes the company to greater financial vulnerability.
FMS
0.83
Health Care Providers & Services Industry
- Max
- 2.41
- Q3
- 1.39
- Median
- 0.74
- Q1
- 0.46
- Min
- 0.00
FMS’s Debt-to-Equity Ratio of 0.83 is typical for the Health Care Providers & Services industry, indicating its use of leverage is in line with the sector norm. This suggests a balanced approach to its capital structure.
Interest Coverage Ratio (TTM)
EXAS
-15.18
Biotechnology Industry
- Max
- 72.37
- Q3
- 1.71
- Median
- -15.18
- Q1
- -65.75
- Min
- -166.46
EXAS has a negative Interest Coverage Ratio of -15.18. This indicates that its earnings were insufficient to cover even its operational costs, let alone its interest payments, signaling significant financial distress.
FMS
5.73
Health Care Providers & Services Industry
- Max
- 14.47
- Q3
- 7.46
- Median
- 4.52
- Q1
- 2.04
- Min
- -4.44
FMS’s Interest Coverage Ratio of 5.73 is positioned comfortably within the norm for the Health Care Providers & Services industry, indicating a standard and healthy capacity to cover its interest payments.
Financial Strength at a Glance
| Symbol | EXAS | FMS |
|---|---|---|
| Current Ratio (MRQ) | 2.72 | 1.44 |
| Quick Ratio (MRQ) | 2.24 | 1.08 |
| Debt-to-Equity Ratio (MRQ) | 0.94 | 0.83 |
| Interest Coverage Ratio (TTM) | -15.18 | 5.73 |
Growth
Revenue Growth
EPS Growth
Dividend
Dividend Yield (TTM)
EXAS
0.00%
Biotechnology Industry
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
EXAS currently does not pay a dividend, resulting in a yield of 0%. This is a common strategy for growth-focused companies that prioritize reinvesting earnings, though it may be less typical in mature, income-oriented sectors.
FMS
3.59%
Health Care Providers & Services Industry
- Max
- 5.51%
- Q3
- 2.66%
- Median
- 1.06%
- Q1
- 0.00%
- Min
- 0.00%
With a Dividend Yield of 3.59%, FMS offers a more attractive income stream than most of its peers in the Health Care Providers & Services industry, signaling a strong commitment to shareholder returns.
Dividend Payout Ratio (TTM)
EXAS
0.00%
Biotechnology Industry
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
EXAS has a Dividend Payout Ratio of 0%, indicating it does not currently pay a dividend. This is a common strategy for growth-oriented companies that reinvest all profits back into the business.
FMS
187.56%
Health Care Providers & Services Industry
- Max
- 187.56%
- Q3
- 81.14%
- Median
- 33.42%
- Q1
- 0.00%
- Min
- 0.00%
FMS’s Dividend Payout Ratio of 187.56% is in the upper quartile for the Health Care Providers & Services industry. This indicates a strong commitment to shareholder returns but also suggests that a smaller portion of earnings is retained for reinvestment compared to many peers.
Dividend at a Glance
| Symbol | EXAS | FMS |
|---|---|---|
| Dividend Yield (TTM) | 0.00% | 3.59% |
| Dividend Payout Ratio (TTM) | 0.00% | 187.56% |
Valuation
Price-to-Earnings Ratio (TTM)
EXAS
--
Biotechnology Industry
- Max
- 115.91
- Q3
- 56.76
- Median
- 21.80
- Q1
- 15.79
- Min
- 4.51
P/E Ratio data for EXAS is currently unavailable.
FMS
17.91
Health Care Providers & Services Industry
- Max
- 48.86
- Q3
- 32.22
- Median
- 21.78
- Q1
- 13.97
- Min
- 8.01
FMS’s P/E Ratio of 17.91 is within the middle range for the Health Care Providers & Services industry. This suggests its valuation is in line with the sector average, representing neither a significant premium nor a discount compared to its peers.
Price-to-Sales Ratio (TTM)
EXAS
4.12
Biotechnology Industry
- Max
- 58.56
- Q3
- 29.31
- Median
- 8.30
- Q1
- 4.89
- Min
- 0.86
In the lower quartile for the Biotechnology industry, EXAS’s P/S Ratio of 4.12 indicates its revenue is valued more conservatively than most of its peers. This could present a compelling opportunity if the market has overlooked its sales-generating capabilities.
FMS
0.60
Health Care Providers & Services Industry
- Max
- 3.66
- Q3
- 1.64
- Median
- 0.72
- Q1
- 0.27
- Min
- 0.10
FMS’s P/S Ratio of 0.60 aligns with the market consensus for the Health Care Providers & Services industry. This suggests its valuation, based on sales, is seen as standard and is on par with its competitors.
Price-to-Book Ratio (MRQ)
EXAS
4.14
Biotechnology Industry
- Max
- 17.92
- Q3
- 10.38
- Median
- 4.78
- Q1
- 2.85
- Min
- 0.78
EXAS’s P/B Ratio of 4.14 is within the conventional range for the Biotechnology industry. This shows a balanced market view, where the stock’s price is neither at a significant premium nor a discount to the book value of its peers.
FMS
1.07
Health Care Providers & Services Industry
- Max
- 7.33
- Q3
- 4.33
- Median
- 2.48
- Q1
- 1.31
- Min
- 0.65
FMS’s P/B Ratio of 1.07 is in the lower quartile for the Health Care Providers & Services industry. From a value investing perspective, this is favorable, as it suggests the stock is trading at a discount to its net asset value and may offer a greater margin of safety.
Valuation at a Glance
| Symbol | EXAS | FMS |
|---|---|---|
| Price-to-Earnings Ratio (TTM) | -- | 17.91 |
| Price-to-Sales Ratio (TTM) | 4.12 | 0.60 |
| Price-to-Book Ratio (MRQ) | 4.14 | 1.07 |
| Price-to-Free Cash Flow Ratio (TTM) | 51.33 | 5.83 |